TScan Therapeutics Says FDA Granted Regenerative Medicine Advanced Therapy Designation To TSC-100 And TSC-101
Portfolio Pulse from Benzinga Newsdesk
TScan Therapeutics announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its two lead TCR-T therapy candidates, TSC-100 and TSC-101, for the treatment of heme malignancies.
May 29, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TScan Therapeutics' TSC-100 and TSC-101 have received FDA RMAT designation, which is likely to accelerate their development and approval process, potentially boosting the company's stock price.
The FDA's RMAT designation is a significant regulatory milestone that can expedite the development and approval of TScan's lead therapy candidates. This is likely to be viewed positively by investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100